Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease. The market watches the stock for commercial durability, pipeline replacement, and the pace at which new assets offset lifecycle pressure.

Recent company news

BMYZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

BMYZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

BMYGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

BMYMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 57.58 USD
Market cap: 117.58B USD
Exchange: NYSE
Sector: Biopharmaceuticals
Location: Princeton, New Jersey

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Related news

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

BMYBristol-Myers Squibb Company

Recent company news

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data